Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCalnex Solutio. Regulatory News (CLX)

Share Price Information for Calnex Solutio. (CLX)

Share Price is delayed by 15 minutes
Get Live Data
68.50    0.00 (0.00%)
Bid:
67.00
Ask:
70.00
Spread: 3.00 (4.478%)
Market Cap: £60.33m
CLX Live PriceLast checked at - London Stock Exchange

Intraday Calnex Solutio. Share Chart

Director Dealing

25 Jan 2022 10:00

RNS Number : 5579Z
Calnex Solutions PLC
25 January 2022
 

25 January 2022

Calnex Solutions plc

("Calnex" or the "Company")

Director Dealing

Calnex Solutions plc (AIM: CLX), an established provided of test and measurement solutions for the global telecommunications sector, was informed on 21 January 2022 that Ann Budge, Non-executive Director of the Company, has sold a 654,621 ordinary shares in the Company at a price of 125 pence per share.

Following this transaction, Ann Budge is interested in a total of 2,000,000 ordinary shares, representing 2.3 per cent. of the issued share capital of the Company.

For more information, please contact:

Calnex Solutions plc

Via Alma PR

Tommy Cook, Chief Executive Officer

Ashleigh Greenan, Chief Financial Officer

Cenkos Securities plc - NOMAD

+44 (0)131 220 6939

Derrick Lee, Peter Lynch

Alma PR

+ 44(0) 20 3405 0213

Caroline Forde, Hannah Campbell, Joe Pederzolli

 

The information in the below notification is disclosed in accordance with Article 19 of the EU Market Abuse Regulation.

1

 

Details of the person discharging managerial responsibilities ("PDMR") / person closely associated ("PCA")

a)

Name

 Mrs Ann Cochrane Cook Wallace Budge

2

Reason for the notification

a)

Position/status

Non-executive Director

b)

Initial notification /Amendment

Initial notification

3

 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Calnex Solutions plc

b)

LEI

213800GY6TURGL3HYT04

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

Ordinary shares of 0.125 pence each

Identification code

GB00BMBK7016

b)

Nature of the transaction

Sale of Ordinary Shares

c)

 

Price(s) and volume(s)

 Date

Price(s)

Volume(s)

18 January 2022

£1.25

654,621

d)

 

Aggregated information

- Aggregated volume

654,621 ordinary shares

- Price

£818,276.25

e)

Date of the transaction

18 January 2022

f)

Place of the transaction

London Stock Exchange (AIM: CLX)

 

For more information, please contact:

Calnex Solutions plc

Via Alma PR

Tommy Cook, Chief Executive Officer

Ashleigh Greenan, Chief Financial Officer

Cenkos Securities plc - Nomad

+44 (0)131 220 6939

Derrick Lee / Peter Lynch

Alma PR

+ 44(0) 20 3405 0213

Caroline Forde, Harriet Jackson, Joe Pederzolli

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHGCGDBCUDDGDU
Date   Source Headline
1st Jun 20267:30 amRNSDirector Dealing
29th May 20263:00 pmRNSExercise of Options and Total Voting Rights
26th May 20267:00 amRNSFinal Results
14th May 20267:00 amRNSNotice of Presentations
13th Apr 20267:00 amRNSFY26 Trading Update and Notice of Results
30th Mar 20267:00 amRNSHolding(s) in Company
26th Nov 20257:30 amRNSDirector Dealing
18th Nov 20257:00 amRNSInterim Results
6th Nov 202511:30 amRNS-RCalnex and Viavi Partnership
30th Oct 20257:00 amRNSNotice of Results and Presentations
8th Oct 20252:08 pmRNSExercise of Options and Total Voting Rights
16th Sep 20259:09 amRNSExercise of Options and Total Voting Rights
14th Aug 20254:12 pmRNSResult of AGM
14th Aug 20257:00 amRNSAGM Statement
15th Jul 20257:00 amRNSNotice of AGM and posting of Annual Report
16th Jun 20259:52 amRNSLong-Term Incentive Plan Awards
10th Jun 202511:59 amRNSDirector Dealing
20th May 20257:00 amRNSFinal Results
15th May 20257:00 amRNSNotice of Investor Presentation
8th Apr 20257:00 amRNSFY25 Trading Update and Notice of Results
14th Mar 20257:00 amRNSDirector Dealing
29th Jan 202510:48 amRNSExercise of Options
19th Nov 20247:00 amRNSInterim Results
4th Nov 20247:00 amRNSNotice of Results and Investor Presentation
8th Oct 20247:00 amRNSDirector/PDMR Dealing
2nd Oct 20244:57 pmRNSResult of General Meeting
6th Sep 20247:00 amRNSNotice of General Meeting
22nd Aug 20245:18 pmRNSResult of AGM
22nd Aug 20247:00 amRNSAGM Statement
18th Jul 20249:08 amRNSNotice of AGM
17th Jul 20242:00 pmRNSLong-Term Incentive Plan Awards
21st May 20247:00 amRNSFY24 Final Results
10th Apr 20247:00 amRNSNotice of Investor Presentation
3rd Apr 20247:00 amRNSFY24 Trading Update and Notice of Results
21st Feb 20249:28 amRNSExercise of Options
14th Feb 20241:08 pmRNSExercise of Options
12th Dec 20233:47 pmRNSPDMR Dealings
21st Nov 20237:00 amRNSInterim Results
1st Nov 202312:24 pmRNSChange of Nominated Adviser
26th Oct 20237:00 amRNSNotice of Investor Presentation
10th Oct 20233:17 pmRNSTrading Update and Notice of Results
25th Aug 20234:36 pmRNSPDMR Dealings
16th Aug 20231:22 pmRNSResult of AGM
16th Aug 20237:00 amRNSAGM Statement
11th Aug 20232:00 pmRNSLong-Term Incentive Plan Awards
17th Jul 20237:00 amRNSNotice of AGM
12th Jul 202312:05 pmRNSDirector/PDMR Dealings
12th Jun 20234:34 pmRNSPDMR Dealings
23rd May 20237:00 amRNSFY23 Final Results
11th May 20239:00 amRNSPDMR Dealings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.